Here’s how PhaseV uses AI to optimize clinical trials to speed clinical development

“Clinical development is the longest and most expensive part to get a drug or medical device to market,” explained Dr. Raviv Pryluk, CEO and Co-Founder of PhaseV. The company, which has offices in Boston and Tel Aviv, describes itself as an AI software company that optimizes clinical development. “And it's associated with a tremendous amount of failures, and we are helping sponsors, pharma companies, biotech, and CROs to make better decisions by avoiding one of the most common pitfalls while drugs are constantly failing.”

Dr. Pryluk spoke to CTech during Calcalist’s Mind The Tech conference in New York. PhaseV was also named as one of the Top 10 Israeli startups to watch out for in 2025 by Qumra Capital.

The company was founded in 2023 by Dr. Pryluk and Elad Berkman, who serves as CTO, and employs 23 people. Its platform allows for increased efficiency and effectiveness of drugs and clinical trials while maximizing benefits for patients and has raised $15 million to date.

“So all of us as family members or friends that have illnesses, diseases, so it's all around us,” he explained. “And when we started to study the space, we've learned that there's a lot of biology that is out there and can cure patients, but can't reach patients due to clinical development and the fact that they are failing in clinical trials. So we start asking what we need to do to increase the success rate.”

According to Dr. Pryluk, trials have a 90% failure rate, and it takes more than 10 years and more than $3 billion to take drugs into the market. He claims it is because we are not choosing the right indications in trials. “We are not executing the trial appropriately, and we are not leveraging the data. So we've built a software AI platform that is really guiding those decisions and dramatically increasing the probability of success.”

You can watch the entire exchange in the video above.